منابع مشابه
Lipid-lowering therapy: who can benefit?
Cardiovascular disease (CVD) is the leading cause of death in the US. Despite the decline in CVD-associated mortality rates in recent years, coronary heart disease (CHD) still causes one in every six deaths in this country. Because most CHD risk factors are modifiable (eg, smoking, hypertension, obesity, onset of type 2 diabetes, and dyslipidemia), cardiovascular risk can be reduced by timely a...
متن کاملRituximab for idiopathic membranous nephropathy: who can benefit?
Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), but response to treatment may vary from patient to patient. The association between baseline clinical, laboratory, and histology covariates and proteinuria reduction was evaluated retrospectively by multiple linear regression analysis at 3 mo after rituximab therapy in 14 patients with IMN with p...
متن کاملCurrent status of retinoid chemoprevention of lung cancer.
Clinical trials have suggested that retinoid chemoprevention prevents the development of second primary tumors following head and neck or non-small-cell lung cancer. The findings of these initial studies are now being evaluated in large multi-institution chemoprevention trials. If successful, these ongoing trials will establish the clinical role of retinoids in lung cancer prevention. The findi...
متن کاملRetinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis.
Chemoprevention is a clinical strategy to block or reverse carcinogenesis before the development of invasive cancer. Studies of chemoprevention in the lungs and upper aerodigestive tract have relied on the field carcinogenesis hypothesis, which predicts that diffuse epithelial injury will result from exposure of that epithelium to carcinogens. This hypothesis is supported by the frequent occurr...
متن کاملRetinoid chemoprevention trials: cyclin D1 in the crosshairs.
Sarah J. Freemantle, Yongli Guo and Ethan Dmitrovsky Successful clinical cancer chemoprevention with retinoids was promised by compelling preclinical and early clinical evidence. Indeed, the concept of cancer chemoprevention came largely from studies showing retinoid suppression of epithelial carcinogenesis (1–4). Yet, randomized phase III intergroup chemoprevention trials with the classic reti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Pharmacology Reports
سال: 2015
ISSN: 2198-641X
DOI: 10.1007/s40495-015-0036-8